Comparing PET/CT imaging methods in multiple myeloma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the imaging findings of amino acid PET/CT with FDG PET/CT in patients diagnosed with multiple myeloma. The focus is on evaluating which imaging technique provides better insights for treatment planning, particularly for those eligible for autologous stem cell transplantation (ASCT). By analyzing the results from these two imaging modalities, the study seeks to enhance diagnostic accuracy and treatment outcomes for myeloma patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Multiple myeloma patients suitable for ASCT treatment

Exclusion Criteria:

* Patients with contraindications to ASCT treatment

Where it's running

• Oslo University Hosptal
  Oslo, Norway Recruiting

Study contacts

• Study coordinator: Mona-Elisabeth Revheim, MD, PhD, MHA
• Email: monar@ous-hf.no
• Phone: +4790659373

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors

  A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885436

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma

  This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.

  Recruiting Jules Bordet Institute · Anderlecht, Brussels Capital and 2 other locations · NCT07674498

• Infectious complications in blood cancer patients treated with bispecific antibodies

  This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.

  Recruiting at 2 sites Infanta Leonor University Hospital · Madrid, Madrid and 1 other locations · NCT07609576

• Mapping individual multiple myeloma biology to understand relapse and treatment resistance

  This project will test whether combining clinical records with whole-genome and RNA sequencing plus blood tumor markers in people with multiple myeloma can reveal features that explain relapse and treatment resistance.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07582354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.